CERCA
MCID: CRV035
MIFTS: 76

Cervical Cancer (CERCA)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer 58 39 12 77 76 38 56 44 3 15 64 74
Uterine Cervical Neoplasms 6 45
Uterine Cervical Neoplasm 12 74
Cervical Cancer, Somatic 58 13
Cervix Cancer 12 76
Neoplasm of Uterine Cervix 12
Tumor of the Cervix Uteri 12
Cancer, Cervical, Somatic 41
Malignant Tumor of Cervix 74
Uterine Cervical Cancer 76
Cervix Uteri Cancer 12
Neoplasms Cervical 56
Cervical Neoplasm 12
Cervix Carcinoma 74
Cerca 76

Characteristics:

HPO:

33
cervical cancer:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:4362
OMIM 58 603956
KEGG 38 H00030
ICD9CM 36 180 180.9
MeSH 45 D002583
NCIt 51 C2940 C9311
SNOMED-CT 69 93752005
ICD10 34 C53 C53.9
SNOMED-CT via HPO 70 108369006 124975008 363346000

Summaries for Cervical Cancer

MedlinePlus : 44 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasms, is related to cervix carcinoma and cervix disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : 12 A female reproductive organ cancer that is located in the cervix.

CDC : 3 Early on, cervical cancer may not cause signs and symptoms. Advanced cervical cancer may cause bleeding or discharge from the vagina that is not normal for you, such as bleeding after sex. If you have any of these signs, see your doctor. They may be caused by something other than cancer, but the only way to know is to see your doctor.

UniProtKB/Swiss-Prot : 76 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : 64 About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer.The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : 77 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Description from OMIM: 603956

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)
# Related Disease Score Top Affiliating Genes
1 cervix carcinoma 33.1 FGFR3 STAT3 TP53
2 cervix disease 32.7 AKT1 CCND1 CTNNB1 TP53
3 papilloma 32.1 CCND1 FGFR3 PTEN TP53
4 squamous cell carcinoma 31.9 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HOTAIR
5 adenocarcinoma 31.4 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6 breast cancer 31.4 AKT1 CCND1 CTNNB1 ERBB2 GNAS HOTAIR
7 endometrial cancer 31.3 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
8 ovarian cancer 31.2 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
9 sarcoma 31.2 CTNNB1 HOTAIR HRAS MTOR PIK3CA TP53
10 lung cancer 31.0 AKT1 CCND1 ERBB2 FGFR3 HOTAIR HRAS
11 kaposi sarcoma 30.9 AKT1 MTOR STAT3 TP53
12 prostate cancer 30.9 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
13 gastric cancer 30.8 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
14 colorectal cancer 30.8 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15 ovarian cancer 1 30.7 AKT1 ERBB2 PIK3CA TP53
16 hepatocellular carcinoma 30.7 AKT1 CCEPR CCND1 CTNNB1 GNAS HOTAIR
17 lung cancer susceptibility 3 30.7 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
18 small cell cancer of the lung 30.7 AKT1 HOTAIR MIR21 PIK3CA PTEN TP53
19 colorectal adenoma 30.6 CTNNB1 HRAS TP53
20 adenoma 30.6 CCND1 CTNNB1 GNAS SMAD4 TP53
21 esophageal cancer 30.6 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
22 carcinosarcoma 30.6 CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
23 uterine carcinosarcoma 30.6 CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
24 tongue squamous cell carcinoma 30.5 AKT1 CTNNB1 MIR21 TP53
25 peutz-jeghers syndrome 30.5 CTNNB1 PTEN SMAD4 TP53
26 penile cancer 30.5 CCND1 PIK3CA TP53
27 bladder cancer 30.5 CCEPR CCND1 ERBB2 FGFR3 HOTAIR HRAS
28 osteogenic sarcoma 30.5 AKT1 HOTAIR PVT1 TP53
29 pancreas adenocarcinoma 30.5 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
30 oral cancer 30.4 CCND1 MIR21 TP53
31 primitive neuroectodermal tumor of the cervix uteri 12.6
32 malignant germ cell tumor of the cervix uteri 12.5
33 cervical intraepithelial neoplasia 11.5
34 carcinosarcoma of the cervix uteri 11.4
35 radiation proctitis 11.3
36 cervical carcinosarcoma 11.0
37 cervix melanoma 11.0
38 cervix endometrial stromal tumor 11.0
39 diethylstilbestrol syndrome 11.0
40 glioblastoma multiforme 10.9 AKT1 CCND1 ERBB2 MIR21 MTOR PIK3CA
41 medulloblastoma 10.9 AKT1 CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA
42 glioblastoma 10.8 AKT1 CCND1 ERBB2 HOTAIR HRAS MIR21
43 uterine anomalies 10.8 AKT1 CCND1 CTNNB1 ERBB2 PIK3CA PTEN
44 cholangiocarcinoma 10.8 AKT1 CCND1 CTNNB1 ERBB2 MIR21 MTOR
45 estrogen-receptor positive breast cancer 10.8 AKT1 CCND1 ERBB2 MTOR PIK3CA TP53
46 respiratory system cancer 10.8 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
47 bladder disease 10.8 AKT1 CCND1 ERBB2 FGFR3 TP53
48 glioma 10.8 CCND1 ERBB2 HOTAIR MIR21 PIK3CA PTEN
49 adenoid cystic carcinoma 10.8 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
50 adamantinoma of long bones 10.8 CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA PTEN

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:



Diseases related to Cervical Cancer

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

33
# Description HPO Frequency HPO Source Accession
1 neoplasm 33 HP:0002664
2 abnormality of the cervical spine 33 HP:0003319

Clinical features from OMIM:

603956

UMLS symptoms related to Cervical Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

27 (show top 50) (show all 57)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.56 MTOR
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.56 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.56 MTOR SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.56 PIK3CA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.56 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.56 PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.56 PTEN CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.56 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.56 AKT1 MTOR PIK3CA PTEN CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.56 CCND1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.56 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.56 PTEN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.56 AKT1 PIK3CA CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.56 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.56 SMAD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.56 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.56 SMAD4 CCND1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.56 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.56 PTEN
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.56 SMAD4 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.56 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.56 AKT1 MTOR PIK3CA PTEN SMAD4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.56 SMAD4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.56 SMAD4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.56 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.56 AKT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.56 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.56 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.56 AKT1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.56 MTOR SMAD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.56 SMAD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.56 AKT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.56 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.56 AKT1 MTOR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.56 PTEN
36 Decreased viability GR00055-A-2 10.35 HRAS MTOR PIK3CA
37 Decreased viability GR00221-A-1 10.35 AKT1 FGFR3 HRAS MTOR PIK3CA
38 Decreased viability GR00221-A-2 10.35 AKT1 FGFR3 HRAS PIK3CA
39 Decreased viability GR00221-A-3 10.35 AKT1 FGFR3 HRAS
40 Decreased viability GR00221-A-4 10.35 AKT1 MTOR PIK3CA
41 Decreased viability GR00342-S-1 10.35 MTOR
42 Decreased viability GR00342-S-2 10.35 MTOR
43 Decreased viability GR00402-S-2 10.35 AKT1 FGFR3 HRAS MTOR PIK3CA
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.17 FGFR3
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.17 ERBB2
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.17 MTOR
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.17 AKT1
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.17 PIK3CA
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.17 MTOR PIK3CA
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.17 FGFR3

MGI Mouse Phenotypes related to Cervical Cancer:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2 cardiovascular system MP:0005385 10.42 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
3 cellular MP:0005384 10.42 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4 growth/size/body region MP:0005378 10.41 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
5 homeostasis/metabolism MP:0005376 10.39 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6 endocrine/exocrine gland MP:0005379 10.35 AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
7 integument MP:0010771 10.34 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
8 mortality/aging MP:0010768 10.32 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
9 immune system MP:0005387 10.31 AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
10 craniofacial MP:0005382 10.3 CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
11 hematopoietic system MP:0005397 10.3 AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
12 digestive/alimentary MP:0005381 10.29 CCND1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
13 embryo MP:0005380 10.28 AKT1 CTNNB1 ERBB2 MTOR NFE2L2 PIK3CA
14 neoplasm MP:0002006 10.25 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15 nervous system MP:0003631 10.25 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
16 adipose tissue MP:0005375 10.22 AKT1 GNAS MTOR NFE2L2 PIK3CA PTEN
17 muscle MP:0005369 10.16 AKT1 CTNNB1 ERBB2 GNAS MTOR PIK3CA
18 normal MP:0002873 10.13 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19 liver/biliary system MP:0005370 10.1 AKT1 CTNNB1 GNAS NFE2L2 PTEN SMAD4
20 limbs/digits/tail MP:0005371 10.05 CTNNB1 ERBB2 FGFR3 GNAS PTEN SMAD4
21 renal/urinary system MP:0005367 9.96 CTNNB1 FGFR3 GNAS HRAS MTOR NFE2L2
22 no phenotypic analysis MP:0003012 9.91 CTNNB1 FGFR3 GNAS HRAS MTOR PIK3CA
23 reproductive system MP:0005389 9.85 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 PIK3CA
24 respiratory system MP:0005388 9.73 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
25 skeleton MP:0005390 9.47 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: 64

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Peppermint Approved Phase 4
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
6
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
7
Meperidine Approved Phase 4 57-42-1 4058
8
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
9
Iron Approved, Experimental Phase 4,Phase 1,Phase 2 7439-89-6, 15438-31-0 27284 23925
10
Ferrous fumarate Approved Phase 4 141-01-5
11
Polihexanide Approved, Investigational Phase 4 28757-47-3
12
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
13
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
14
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 54-11-5 89594 942
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
17
Nevirapine Approved Phase 4 129618-40-2 4463
18
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 54670067 5785
19 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Monophosphoryl lipid A Phase 4
22 Cholinergic Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Muscarinic Agonists Phase 4
27 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Epoetin alfa Phase 4,Phase 3 113427-24-0
31 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
32 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Narcotics Phase 4,Phase 3,Not Applicable,Early Phase 1
34 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
35 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
36 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Adjuvants, Anesthesia Phase 4,Phase 3,Not Applicable
40 Anesthetics, General Phase 4,Phase 3,Not Applicable
41 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Psychotropic Drugs Phase 4,Phase 3,Phase 2
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
48 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
50 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1434)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Unknown status NCT02629510 Phase 4 Tachosil
2 FASTER-Tlalpan Study Unknown status NCT03105856 Phase 4
3 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
4 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
5 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
6 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
7 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Unknown status NCT01031069 Phase 4
8 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
9 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
10 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
11 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
12 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
13 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
14 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
15 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Completed NCT02837926 Phase 4
16 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
17 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
18 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
19 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
20 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
21 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
22 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
23 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
24 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
25 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
26 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
27 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
28 The KEN SHE Study on HPV-vaccine Efficacy Enrolling by invitation NCT03675256 Phase 4
29 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
30 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
31 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
32 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
33 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
34 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
35 Postpartum HPV Vaccination Recruiting NCT03451071 Phase 4 Gardasil9
36 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
37 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
38 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
39 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
40 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
41 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
42 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
43 Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer Unknown status NCT02446652 Phase 3 Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
44 Adjuvant Chemotherapy for Locally Advanced Cervical Cancer Unknown status NCT02036164 Phase 3 Cisplatin;Paclitaxel;Carboplatin
45 Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
46 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
47 Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
48 Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer Unknown status NCT01999933 Phase 2, Phase 3 cisplatin(DDP) weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
49 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
50 Hydralazine Valproate for Cervical Cancer Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Anatomical Context for Cervical Cancer

MalaCards organs/tissues related to Cervical Cancer:

42
Cervix, Testes, Lymph Node, Breast, T Cells, Lung, Uterus

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

20
The Cervix

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 7360)
# Title Authors Year
1
Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1/microRNA-202-3p/periostin axis modulates invasion and epithelial-mesenchymal transition in human cervical cancer. ( 30633360 )
2019
2
Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer. ( 30019594 )
2019
3
Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program. ( 31098856 )
2019
4
Cardiac Tamponade as an Initial Manifestation of Cervical Cancer. ( 30729054 )
2019
5
SURVIVAL OUTCOMES OF ROBOTIC RADICAL HYSTERECTOMY FOR EARLY STAGE CERVICAL CANCER: A 9-YEAR STUDY. ( 31039279 )
2019
6
The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1. ( 31043793 )
2019
7
Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines. ( 31043805 )
2019
8
Towards global elimination of cervical cancer in all groups of women. ( 31044712 )
2019
9
Towards global elimination of cervical cancer in all groups of women. ( 31044713 )
2019
10
Towards global elimination of cervical cancer in all groups of women - Authors' reply. ( 31044714 )
2019
11
Barriers to Cervical Cancer Screening and Treatment in the Dominican Republic: Perspectives of Focus Group Participants in the Santo Domingo Area. ( 31046602 )
2019
12
Smoking Cessation Treatment Needs of Low SES Cervical Cancer Survivors. ( 31046890 )
2019
13
Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells. ( 31048733 )
2019
14
Downregulation of microRNA-205 inhibits cell invasion and angiogenesis of cervical cancer through TSLC1-mediated Akt signaling pathway. ( 31049956 )
2019
15
Cervical cancer - causes and prevention of hpv infections in the opinions of young polish women: a cross-sectional survey. ( 31050976 )
2019
16
Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro. ( 31052347 )
2019
17
Years of Life Lost Due to Cervical Cancer in Poland in 2000 to 2015. ( 31052396 )
2019
18
Re-thinking breast and cervical cancer preventive campaigns in developing countries: the case for interventions at high schools. ( 31053073 )
2019
19
Knowledge, attitudes and practices of cervical cancer prevention among Zambian women and men. ( 31054569 )
2019
20
Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression. ( 31056260 )
2019
21
Modelling risk assessment for cervical cancer in symptomatic Saudi women. ( 31056620 )
2019
22
Simultaneous Metastasis from Cervical Cancer to the Kidney and Paraspinal Muscle: A Case Report. ( 31058031 )
2019
23
Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways. ( 31058344 )
2019
24
PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. ( 31058807 )
2019
25
Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2. ( 31059006 )
2019
26
S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelial‑mesenchymal transition and activating the Wnt/β‑catenin pathway. ( 31059008 )
2019
27
microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. ( 31060525 )
2019
28
Short- and long term outcomes after abdominal radical trachelectomy versus radical hysterectomy for early stage cervical cancer: a systematic review of the literature and meta-analysis. ( 31062151 )
2019
29
Integrated analysis of two-lncRNA signature as a potential prognostic biomarker in cervical cancer: a study based on public database. ( 31065456 )
2019
30
Comparing Receipt of Cervical Cancer Screening and Completion of Human Papillomavirus Vaccination Using a New Construct of Sexual Orientation: A Serial Cross-Sectional Study. ( 31066610 )
2019
31
Cervical cancer - staging and restaging with 18F-FDG PET/CT. ( 31066810 )
2019
32
Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala. ( 31067142 )
2019
33
Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. ( 31067317 )
2019
34
AgNOR Pleomorphic Count as a Tumor Marker in Cervical Carcinogenesis and Feasibility of Its Introduction in Cervical Cancer Screening Programs to Discriminate High-Risk Cases of Squamous Intraepithelial Lesions of the Cervix. ( 31067531 )
2019
35
Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer. ( 31068247 )
2019
36
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. ( 31069132 )
2019
37
Evaluation of cytology as secondary triage in visual inspection after application of 4% acetic acid-based cervical cancer screening program. ( 31069189 )
2019
38
Second primary uterine malignancies after radiation therapy for cervical cancer. ( 31069490 )
2019
39
Contrast-Enhancing Snapshot Narrow-Band Imaging Method for Real-Time Computer-Aided Cervical Cancer Screening. ( 31069586 )
2019
40
Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer. ( 31070018 )
2019
41
Using Low-Cost Virtual Reality Simulation to Build Surgical Capacity for Cervical Cancer Treatment. ( 31070982 )
2019
42
Correction: ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis. ( 31071170 )
2019
43
Assessment of epigenetic alterations and in silico analysis of mutation affecting PTEN expression among Indian cervical cancer patients. ( 31074114 )
2019
44
Stage and histology of cervical cancer in women under 25 years old. ( 31074235 )
2019
45
A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. ( 31074236 )
2019
46
A community-based, cross-sectional study of hrHPV DNA self-sampling-based cervical cancer screening in rural Karnataka, India. ( 31074835 )
2019
47
Effect of Deubiquitinase Ovarian Tumor Domain-Containing Protein 5 (OTUD5) on Radiosensitivity of Cervical Cancer by Regulating the Ubiquitination of Akt and its Mechanism. ( 31075090 )
2019
48
Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. ( 31075122 )
2019
49
Clinical Outcomes in Early Cervical Cancer Patients Treated with Nerve Plane-Sparing Laparoscopic Radical Hysterectomy. ( 31075445 )
2019
50
Fertility-sparing surgery for early-stage cervical cancer: does surgical approach have an impact on disease outcomes? ( 31076039 )
2019

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

76
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Ser249Cys VAR_004149 rs121913483

ClinVar genetic disease variations for Cervical Cancer:

6 (show top 50) (show all 286)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.4(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
4 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
5 TP53 NM_000546.5(TP53): c.747G> T (p.Arg249Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs28934571 GRCh37 Chromosome 17, 7577534: 7577534
6 TP53 NM_000546.5(TP53): c.747G> T (p.Arg249Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs28934571 GRCh38 Chromosome 17, 7674216: 7674216
7 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
8 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
9 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
12 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
14 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
15 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
16 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
17 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
18 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
19 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
20 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
21 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
22 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
25 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
26 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
27 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
28 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
29 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
30 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
31 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
32 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
33 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
34 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
35 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
36 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
37 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
38 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
39 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
40 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
41 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
42 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh37 Chromosome 4, 1806119: 1806119
43 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh38 Chromosome 4, 1804392: 1804392
44 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
45 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh38 Chromosome 4, 1801837: 1801837
46 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh37 Chromosome 4, 1807371: 1807371
47 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh38 Chromosome 4, 1805644: 1805644
48 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
49 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
50 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh37 Chromosome 4, 1803571: 1803571

Copy number variations for Cervical Cancer from CNVD:

7 (show top 50) (show all 142)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13747 1 1 27800000 Gain EPHB2 Cervical cancer
2 16425 1 124300000 247249719 Arm Cervical cancer
3 30310 1 241700000 247249719 Gain Cervical cancer
4 31746 1 30500000 163800000 Gain AIM2 Cervical cancer
5 32175 1 34400000 39600000 Gain CDCA8 Cervical cancer
6 47124 10 89600000 98000000 Loss PTEN Cervical cancer
7 48645 11 101600000 102400000 Amplification MMP1 Cervical cancer
8 48646 11 101600000 102400000 Amplification MMP13 Cervical cancer
9 51761 11 130300000 134452384 Loss Cervical cancer
10 51791 11 130800000 135006516 Loss HNT Cervical cancer
11 51792 11 130800000 135006516 Loss OPCML Cervical cancer
12 55435 11 52900000 134452384 Loss Cervical cancer
13 57095 11 63100000 130300000 Loss INT2 Cervical cancer
14 57096 11 63100000 130300000 Loss MEN1 Cervical cancer
15 57097 6 99389300 99393387 Loss POUF3 Cervical cancer
16 57098 11 63100000 130300000 Loss TRIM29 Cervical cancer
17 59362 11 74700000 85300000 Gain Cervical cancer
18 77051 13 39500000 52200000 Loss RB Cervical cancer
19 81044 14 100400000 106368585 Gain AKT1 Cervical cancer
20 97280 16 1 40700000 Loss Cervical cancer
21 106741 17 1 11200000 Loss TP53 Cervical cancer
22 108734 17 22200000 28800000 Loss CCL2 Cervical cancer
23 109725 17 28500000 29700000 Amplification Cervical cancer
24 109738 17 28800000 35400000 Amplification ERBB2 Cervical cancer
25 111034 17 34900000 35300000 Amplification Cervical cancer
26 111283 17 35400000 54900000 Amplification ABCC3 Cervical cancer
27 112092 17 37856253 37884915 Amplification ERBB2 Cervical cancer
28 112304 17 38544772 38574202 Amplification TOP2A Cervical cancer
29 117589 17 72900000 78774742 Gain Cervical cancer
30 124103 19 1 30200000 Gain Cervical cancer
31 124104 19 1 30200000 Loss Cervical cancer
32 124177 19 1 6900000 Gain SMARCA4 Cervical cancer
33 124219 19 1 6900000 Gain Cervical cancer
34 124597 19 1156797 1179434 Deletion LKB1 Cervical Cancer
35 124598 19 1156797 1179434 Deletion LKB1 Cervical cancer
36 130163 19 47800000 57600000 Gain LIG1 Cervical cancer
37 134165 19 9500000 14500000 Gain Cervical cancer
38 140388 2 197100000 242951149 Loss CASP10 Cervical cancer
39 140389 2 197100000 242951149 Loss CFLAR Cervical cancer
40 140390 2 197100000 242951149 Loss PPP1R7 Cervical cancer
41 151917 20 27100000 28400000 Amplification AHCY Cervical cancer
42 151918 20 27100000 28400000 Amplification ASXL1 Cervical cancer
43 151919 20 27100000 28400000 Amplification C20orf20 Cervical cancer
44 151920 20 27100000 28400000 Amplification E2F1 Cervical cancer
45 151921 20 27100000 28400000 Amplification GSS Cervical cancer
46 151922 20 27100000 28400000 Amplification KIF3B Cervical cancer
47 151923 20 27100000 28400000 Amplification POFUT1 Cervical cancer
48 151924 20 27100000 28400000 Amplification TPX2 Cervical cancer
49 153446 20 37100000 41100000 Gain AIB1 Cervical cancer
50 153736 20 41100000 49200000 Amplification ADNP Cervical cancer

Expression for Cervical Cancer

Search GEO for disease gene expression data for Cervical Cancer.

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Human papillomavirus infection hsa05165
2 Viral carcinogenesis hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.31 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2
Show member pathways
14.16 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HRAS
3
Show member pathways
14.01 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4
Show member pathways
13.84 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
5
Show member pathways
13.84 AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
6
Show member pathways
13.8 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
7
Show member pathways
13.69 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
8
Show member pathways
13.67 AKT1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
9
Show member pathways
13.62 AKT1 CTNNB1 ERBB2 FGFR3 HRAS PIK3CA
10
Show member pathways
13.58 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
11
Show member pathways
13.57 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
12
Show member pathways
13.5 AKT1 CCND1 ERBB2 FGFR3 HRAS PIK3CA
13
Show member pathways
13.42 AKT1 CTNNB1 ERBB2 FGFR3 HRAS PTEN
14
Show member pathways
13.38 AKT1 CCND1 ERBB2 GNAS HRAS MTOR
15
Show member pathways
13.21 AKT1 FGFR3 GNAS HRAS MTOR PTEN
16
Show member pathways
13.17 AKT1 FGFR3 GNAS HRAS MTOR STAT3
17
Show member pathways
13.13 AKT1 CTNNB1 GNAS HRAS STAT3 TP53
18
Show member pathways
13.11 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19
Show member pathways
13.1 AKT1 CTNNB1 HRAS MTOR PIK3CA PTEN
20
Show member pathways
13.09 AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
21
Show member pathways
13.07 AKT1 ERBB2 HRAS MTOR PIK3CA PTEN
22
Show member pathways
13.07 AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
23
Show member pathways
13.06 AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
24
Show member pathways
13.02 AKT1 CCND1 GNAS HRAS PIK3CA STAT3
25
Show member pathways
12.98 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
26
Show member pathways
12.96 AKT1 CCND1 HRAS MTOR PIK3CA PTEN
27
Show member pathways
12.93 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
28
Show member pathways
12.92 AKT1 CTNNB1 GNAS HRAS MTOR
29
Show member pathways
12.91 AKT1 CTNNB1 ERBB2 HRAS MTOR PIK3CA
30
Show member pathways
12.89 AKT1 CTNNB1 FGFR3 GNAS HRAS PIK3CA
31 12.88 AKT1 ERBB2 FGFR3 HRAS TP53
32
Show member pathways
12.87 AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
33
Show member pathways
12.84 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
34
Show member pathways
12.8 AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
35
Show member pathways
12.79 AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
36
Show member pathways
12.77 AKT1 CTNNB1 ERBB2 HRAS PIK3CA STAT3
37
Show member pathways
12.73 AKT1 CCND1 CTNNB1 MTOR STAT3
38
Show member pathways
12.72 AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
39
Show member pathways
12.71 AKT1 GNAS HRAS PIK3CA STAT3
40
Show member pathways
12.7 AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
41
Show member pathways
12.67 AKT1 HRAS MTOR PIK3CA PTEN
42
Show member pathways
12.66 AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
43
Show member pathways
12.63 AKT1 HRAS MTOR PIK3CA STAT3
44
Show member pathways
12.63 AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
45
Show member pathways
12.62 AKT1 CCND1 HRAS MTOR PIK3CA TP53
46
Show member pathways
12.59 AKT1 CCND1 HRAS MTOR PIK3CA STAT3
47 12.58 AKT1 CCND1 CTNNB1 GNAS TP53
48
Show member pathways
12.57 CTNNB1 ERBB2 FGFR3 HRAS MTOR PIK3CA
49 12.57 AKT1 CCND1 CTNNB1 HRAS PIK3CA SMAD4
50
Show member pathways
12.57 AKT1 CCND1 HRAS MTOR PIK3CA PTEN

GO Terms for Cervical Cancer

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 AKT1 CCND1 CTNNB1 ERBB2 GNAS MTOR
2 cytoplasm GO:0005737 9.5 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
3 nucleus GO:0005634 10 AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 AKT1 CTNNB1 HRAS MIR21 MIR214
2 positive regulation of cell proliferation GO:0008284 9.97 AKT1 CCND1 CTNNB1 FGFR3 HRAS MIR21
3 aging GO:0007568 9.96 AKT1 NFE2L2 PTEN STAT3
4 protein autophosphorylation GO:0046777 9.96 AKT1 ERBB2 FGFR3 MTOR
5 positive regulation of MAPK cascade GO:0043410 9.92 CTNNB1 ERBB2 FGFR3 HRAS
6 positive regulation of protein kinase B signaling GO:0051897 9.89 ERBB2 FGFR3 MIR21 MTOR PIK3CA
7 response to estradiol GO:0032355 9.88 CCND1 CTNNB1 PTEN STAT3
8 negative regulation of apoptotic process GO:0043066 9.88 AKT1 CTNNB1 MIR21 PTEN STAT3 TP53
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.87 MIR21 PTEN SMAD4
10 negative regulation of cell death GO:0060548 9.86 NFE2L2 SMAD4 STAT3
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 FGFR3 HRAS MIR21 PTEN
12 negative regulation of cell proliferation GO:0008285 9.86 CTNNB1 HRAS MIR21 MIR214 PTEN SMAD4
13 positive regulation of osteoblast differentiation GO:0045669 9.85 CTNNB1 GNAS MIR21
14 cellular response to growth factor stimulus GO:0071363 9.85 AKT1 CTNNB1 ERBB2
15 response to organic substance GO:0010033 9.85 AKT1 CCND1 PTEN STAT3
16 negative regulation of neuron death GO:1901215 9.84 AKT1 CTNNB1 STAT3
17 protein kinase B signaling GO:0043491 9.8 AKT1 PIK3CA PTEN
18 positive regulation of protein phosphorylation GO:0001934 9.8 AKT1 CCND1 ERBB2 HRAS MIR21 MTOR
19 activation of protein kinase B activity GO:0032148 9.78 AKT1 MIR21 MTOR
20 phosphatidylinositol 3-kinase signaling GO:0014065 9.77 AKT1 ERBB2 PIK3CA
21 cell aging GO:0007569 9.76 HRAS MTOR TP53
22 positive regulation of epithelial to mesenchymal transition GO:0010718 9.73 CTNNB1 MIR21 MTOR SMAD4
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.71 MIR21 MIR214 NFE2L2
24 regulation of mitochondrial membrane permeability GO:0046902 9.7 STAT3 TP53
25 regulation of protein kinase B signaling GO:0051896 9.7 MIR21 MTOR
26 response to leptin GO:0044321 9.7 CCND1 STAT3
27 cellular response to leptin stimulus GO:0044320 9.7 PTEN STAT3
28 regulation of myelination GO:0031641 9.7 AKT1 CTNNB1 MTOR
29 positive regulation of metalloendopeptidase activity GO:1904685 9.69 MIR21 STAT3
30 negative regulation of macroautophagy GO:0016242 9.69 AKT1 MTOR PIK3CA
31 mitotic G1 DNA damage checkpoint GO:0031571 9.68 CCND1 TP53
32 endothelial tube morphogenesis GO:0061154 9.68 CTNNB1 MIR21
33 regulation of glycogen biosynthetic process GO:0005979 9.67 AKT1 MTOR
34 hair follicle placode formation GO:0060789 9.65 CTNNB1 GNAS
35 anoikis GO:0043276 9.65 AKT1 MTOR PIK3CA
36 cellular response to decreased oxygen levels GO:0036294 9.63 AKT1 PTEN
37 negative regulation of cell size GO:0045792 9.63 AKT1 MTOR PTEN
38 cellular response to hypoxia GO:0071456 9.63 AKT1 MIR214 MTOR NFE2L2 PTEN TP53
39 response to UV-A GO:0070141 9.61 AKT1 CCND1
40 cell proliferation GO:0008283 9.56 AKT1 CTNNB1 ERBB2 HRAS PTEN SMAD4
41 positive regulation of transcription by RNA polymerase III GO:0045945 9.4 MTOR
42 positive regulation of gene expression GO:0010628 9.32 AKT1 CTNNB1 ERBB2 HRAS MIR21 MTOR
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 AKT1 CTNNB1 HRAS NFE2L2 SMAD4 STAT3
44 phosphorylation GO:0016310 10.14 AKT1 ERBB2 FGFR3 MTOR PIK3CA STAT3
45 protein phosphorylation GO:0006468 10.13 AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
46 nervous system development GO:0007399 10.11 AKT1 CTNNB1 ERBB2 PTEN STAT3
47 positive regulation of transcription, DNA-templated GO:0045893 10.11 AKT1 CTNNB1 NFE2L2 SMAD4 STAT3 TP53
48 positive regulation of apoptotic process GO:0043065 10.04 AKT1 CTNNB1 MIR21 PTEN TP53
49 response to drug GO:0042493 10.03 CCND1 CTNNB1 GNAS PTEN STAT3
50 cytokine-mediated signaling pathway GO:0019221 10 AKT1 CCND1 PIK3CA STAT3 TP53

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
2 transcription regulatory region DNA binding GO:0044212 9.78 NFE2L2 SMAD4 STAT3 TP53
3 identical protein binding GO:0042802 9.76 AKT1 ERBB2 FGFR3 MTOR PTEN SMAD4
4 nucleotide binding GO:0000166 9.73 ERBB2 FGFR3 HRAS MTOR
5 enzyme binding GO:0019899 9.72 AKT1 CCND1 CTNNB1 PTEN TP53
6 transcription factor binding GO:0008134 9.65 CCND1 CTNNB1 NFE2L2 STAT3 TP53
7 RNA polymerase II transcription factor binding GO:0001085 9.54 CTNNB1 SMAD4 TP53
8 I-SMAD binding GO:0070411 9.49 CTNNB1 SMAD4
9 protein phosphatase binding GO:0019903 9.26 CTNNB1 ERBB2 STAT3 TP53
10 protein kinase binding GO:0019901 9.17 AKT1 CCND1 CTNNB1 MTOR PTEN STAT3
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.16 PIK3CA

Sources for Cervical Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....